Curis Lifesciences Ltd. IPO

Curis Lifesciences is the pharma manufacturer, specializing in manufacturing of a wide range of pharmaceutical products such as Tablets, Capsules, External Preparations, Oral Liquid, Sterile Ophthalmic Ointments. We operate in global as well as domestic markets. We undertake manufacturing ... activities on loan license, Contract Manufacturing and Direct Export basis/Own Brand Marketing basis. In terms of the nature of manufacturing and business activities, our business can be bifurcated in following 3 catagories: 1. Loan License manufacturing: Under this vertical, our company carry outs manufacturing under Loan License arrangement, where all raw materials and excipients are procured and delivered by the client. Further the client provides us with necessary supporting documents and formulations. On instructions of the client our company undertakes manufacturing activities under observation of a chemist, representing the customer. In summary, our company would perform manufacturing activities as a job work on behalf of the loan licensing company for the product. Our customers for loan license manufacturing activities are domestic. 2. Contract Manufacturing: Under this vertical, our company carry outs manufacturing under Contract Manufacturing arrangement, where our Company would be responsible for procuring and handling all ingredients, raw materials, and packaging materials. Further, all necessary supporting documents and formulations required under manufacturing process would be procured / provided by our company. However, the client, is responsible for providing the brand name and product composition. Moreover, all marketing and distribution responsibilities rests with the client. Our customers for contract manufacturing activities can be further bifurcated under two major categories, as follows: a) Merchant Exporters b) Domestic Suppliers 3. Direct Export/Own Brand Manufacturing: Under this vertical, our company manufactures products registered by itself in foreign country and sells the said products in foreign country through its distribution network. All ingredients, including raw materials and packaging materials, are purchased and handled by our company. Additionally, we are responsible for all marketing and distribution activities. The brand name and product composition is owned by us only. Currently, we are engaged in direct export under our own brands in two countries in the Republic of Yemen and Kenya. Read more

Our Company was originally formed and registered as a Partnership Firm under the Partnership Act, 1932 (“Partnership Act”) in the name and style of “M/s Loreto Pharmaceutacals”, pursuant to a deed of partnership dated June 2, 2010. Thereafter " M/s Loreto ... Pharmaceuticals” was converted from Partnership Firm to a Private Limited Company under the Companies Act, 2013 in the name of “Curis Lifesciences Private Limited” and received a certificate of incorporation datedMarch 23, 2016 issued by Assistant Registrar of Companies, Gujarat. Subsequently, our Company was converted into a public limited company and the name of our Company was changed from “Curis Lifesciences Private Limited” to “Curis Lifesciences Limited” vide Special Resolution dated May 6, 2024, the status of the Company was changed to public limited and the fresh certificate of incorporation consequent to conversion, bearing Corporate Identification Number U24230GJ2016PLC086559, was issued on August 9, 2024 by the Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Central Processing Centre. From year 2010 to 2016, our partnership firm was engaged in the marketing and trading of various pharmaceutical products. As a partnership firm, our product portfolio included tablets, capsules, oral liquids, creams, ointments, injections, lotions, oral powders and other nutraceuticals products. We procured finished goods from manufacturers and distributed them to various wholesalers and other clients throught the country.

• Indian pharmaceutical industry is known for its generic medicines and low-cost vaccines globally. Transformed over the years as a vibrant sector, presently the Indian Pharmaceutical industry is the third largest in the world in terms of volume and 14th largest in terms of value. The pharma ... sector currently contributes to around 1.72% of the country’s GDP. • The Indian pharmaceuticals industry is expected to grow 9-11% in the financial year 2024, as per ICRA. • In FY23, the Indian pharma market saw a year-on-year growth of nearly 5%, reaching US$ 49.78 billion. During FY18 to FY23, the Indian pharmaceutical industry logged a compound annual growth rate (CAGR) of 6-8%, primarily driven by an 8% increase in exports and a 6% rise in the domestic market. • Major Segments of the Pharmaceutical Industry are Generic drugs, OTC Medicines and API/Bulk Drugs, Vaccines, Contract Research & Manufacturing, Biosimilars & Biologics. • Market size of India pharmaceuticals industry is expected to reach US$ 65 billion by 2024, ~US$ 130 billion by 2030 and ~US$ 450 billion market by 2047. Read more